Abbott unit to pay $41 million to settle kickback, off-label claims from US whistleblower suit
This article was originally published in Scrip
Abbott Laboratories has agreed to pay $41 million to resolve criminal and civil charges that its Kos Pharmaceuticals unit engaged in kickbacks and off-label marketing related to Advicor (niacin-extended release plus lovastatin tablets) and Niaspan (niacin extended-release), the US Department of Justice (DoJ) said. The allegations stemmed from the filing of a whistleblower suit by former Kos employees, and the whistleblowers will receive $6.4 million from the federal share of the settlement under whistleblower provisions of the False Claims Act.
You may also be interested in...
ChemoCentryx has successfully completed its initial public offering on Nasdaq, raising $45 million to help support its multiple R&D programmes. It sold 4.5 million shares at $10, a somewhat less ambitious debut than it had originally planned in January when it wanted to sell four million shares at $14-$16. The reduced offer is a sign of the challenging nature of the IPO market, but ChemoCentryx's assessment of its own worth was at least closer to the market’s assessment that Cempra which got its IPO away on 6 February at valuation that was less than two-thirds of that implied by its initial prospectus (scripintelligence.com, 7 February 2012).
Ampio Pharmaceuticals, a development-stage company, initially raised $15 million which was boosted to $16.9 million by the exercise of overallotments by brokers. The shares were offered at $3.25, an 8.5% discount to the closing price of $3.66 on 12 July. The market pushed them down slightly further to 3.21 on 13 July.
Verastem, a cancer stem cells startup, has moved quickly to build its pipeline just five months after an initial public offering. Management at the Cambridge, Massachusetts firm believes that recent moves have accelerated Verastem's clinical development plans by a year.